This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biogen Idec, F5: Analysts' New Ratings

Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Biogen Idec (BIIB - Get Report) upgraded at Credit Suisse from Neutral to Outperform. $126 price target. Estimates also boosted, given higher expectations for BG12.

Boston Scientific (BSX - Get Report) rated new Buy at Stifel Nicolaus. $9 price target. Earnings growth could soon begin to accelerate.

F5 Networks (FFIV - Get Report) upgraded at Barclays from Equal Weight to Overweight. $125 price target. Estimates also increased through 2012. F5's revenue pipeline and market are healthy.

Forest Oil (FST - Get Report) upgraded at Stifel from Hold to Buy, Stifel Nicolaus said. $34 price target. Stock has pulled back to an attractive level.

Hexcel (HXL - Get Report) upgraded at Keybanc from Hold to Buy. $28 price target. Company is leveraged to higher commercial aerospace demand.

Polo Ralph Lauren (RL - Get Report) rated new Outperform at Wells. Recent investments should help future growth.

Synovus Financial (SNV) downgraded at Wunderlich from Buy to Hold. $2.50 price target. Company still faces significant earnings headwinds.

Susquehanna (SUSQ) upgraded at KBW from Market Perform to Outperform, Keefe, Bruyette & Woods said. Valuation call, based on a $10 price target.

Western Refining (WNR) upgraded at Deutsche from Hold to Buy, Deutsche Bank said. $24 price target. Company is leveraged to a wider Brent-WTI spread.

VCA Antech (WOOF) rated new Outperform at Barrington Research. $28 price target. Company generates significant free cash flow.



End of report.

This article was written by a staff member of TheStreet.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
FST $0.20 -4.76%
BSX $17.74 0.00%
BIIB $386.22 0.00%
FFIV $123.37 0.00%
HXL $49.58 0.00%

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs